CDS1

Chr 4

CDP-diacylglycerol synthase 1

Also known as: CDS 1

Breakdown products of phosphoinositides are ubiquitous second messengers that function downstream of many G protein-coupled receptors and tyrosine kinases regulating cell growth, calcium metabolism, and protein kinase C activity. This gene encodes an enzyme which regulates the amount of phosphatidylinositol available for signaling by catalyzing the conversion of phosphatidic acid to CDP-diacylglycerol. This enzyme is an integral membrane protein localized to two subcellular domains, the matrix side of the inner mitochondrial membrane where it is thought to be involved in the synthesis of phosphatidylglycerol and cardiolipin and the cytoplasmic side of the endoplasmic reticulum where it functions in phosphatidylinositol biosynthesis. Two genes encoding this enzyme have been identified in humans, one mapping to human chromosome 4q21 and a second to 20p13. [provided by RefSeq, Jul 2008]

OMIMResearchGenerating clinical summary…

Primary Disease Associations & Inheritance

UniProtTumor predisposition syndrome 4
UniProtProstate cancer
UniProtOsteogenic sarcoma
UniProtBreast cancer
6
Active trials
21
Pubs (1 yr)
P/LP submissions
P/LP missense
0.65
LOEUF
Multiple*
Mechanism· predicted

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Tolerant — LoF & missense variants common in population
LoF Constraint?
0.65LOEUF
pLI 0.001
Z-score 2.91
OE 0.38 (0.240.65)
Tolerant

Typical tolerance to LoF variation

Missense Constraint?
1.48Z-score
OE missense 0.73 (0.640.83)
170 obs / 233.8 exp
Tolerant

Mild missense constraint

Observed / Expected Ratios?
LoF OE?0.38 (0.240.65)
00.351.4
Missense OE?0.73 (0.640.83)
00.61.4
Synonymous OE?0.71
01.21.6
LoF obs/exp: 10 / 26.0Missense obs/exp: 170 / 233.8Syn Z: 2.06

ClinVar Variant Classifications

0 submitted variants in ClinVar

Protein Context — Lollipop Plot

CDS1 · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

BRCA1 MutationBRCA2 MutationBRCA Mutation

Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors

RECRUITING
NCT06177171Phase PHASE1Varun Monga, MBBSStarted 2024-02-07
OlaparibASTX727
Prostate CancerBRCA MutationMismatch Repair Gene Mutation

The GENPET Study - An Imaging Study of FCH-PET-CT in Men With Prostate Cancer and a DNA Repair Gene Mutation.

RECRUITING
NCT05097274Institute of Cancer Research, United KingdomStarted 2015-10-15
MRI pelvis or CT imaging under clinical management for Pr CaWhole body bone scan imagingPET-CT imaging
Lynch SyndromeLi Fraumeni SyndromePTEN Hamartoma Syndrome

Video Capsule Examination in Patients With Lynch Syndrome

RECRUITING
NCT06712095Phase NARoyal Marsden NHS Foundation TrustStarted 2024-03-04
Video capsule investigation
Metastatic Breast CancerInvasive Breast CancerSomatic Mutation Breast Cancer (BRCA1)

Olaparib In Metastatic Breast Cancer

ACTIVE NOT RECRUITING
NCT03344965Phase PHASE2Beth Israel Deaconess Medical CenterStarted 2018-04-01
Olaparib
BRCA1 MutationPOLD1 Gene MutationCDKN2A Mutation

An Intervention to Increase Genetic Testing in Families Who May Share a Gene Mutation Related to Cancer Risk and An Intervention to Help Patients and Their Primary Care Providers Stay Up-to-date About Uncertain Genetic Test Results

RECRUITING
NCT05420064Phase NAMemorial Sloan Kettering Cancer CenterStarted 2022-12-01
Intervention Arm At-risk Relative/ARR ContactsMyGene PortalStandard of Care
Breast CancerDuctal CarcinomaEstrogen-receptor-positive Breast Cancer

Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk for Breast Cancer

NOT YET RECRUITING
NCT07499999Phase PHASE2Dana-Farber Cancer InstituteStarted 2026-09-09
ExemestaneTamoxifen